This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Many patients with interstitial lung disease (ILD) do not receive a timely and accurate diagnosis prior to considerable disease progression. Management guidelines are vague and treatment options have been limited, leading to negative health outcomes and decreased quality of life. Advances in diagnostic strategies, recently approved therapies, and new clinical trial data, however, are changing best practices in the diagnosis and treatment of ILD. This activity will examine the signs and symptoms of ILD, strategies for timely diagnosis and accurate classification, and pharmacologic and nonpharmacologic treatment options.
This activity is intended for pulmonologists, internal medicine specialists, primary care clinicians, radiologists, and other clinicians who encounter ILD.
Upon completion of this educational activity, participants should be able to:
Review the diagnosis and classification of ILD disorders
Discuss advances in ILD diagnosis and assessment
Outline treatment strategies for ILD
Recognize the importance of treating comorbidities
Conflict Of Interest Disclosure Policy
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Presenter Mary Beth Scholand, MD Associate Professor of Pulmonary Medicine Director of the Interstitial Lung Disease Clinic University of Utah Salt Lake City, UT
Dr. Scholand has disclosed the following: Speakers Bureau: Roche/Genentech Consultant: Boehringer Ingelheim, Roche/Genentech
Additional Content Development Faculty Sonye K. Danoff, MD, PhD Associate Professor of Medicine Co-Director, Johns Hopkins ILD/IPF Program Associate Director, Johns Hopkins Myositis Center Baltimore, MD
Dr. Danoff has disclosed the following: Grant/Research Support: Boehringer Ingelheim, Roche/Genentech Consultant: Boehringer Ingelheim
Kevin R. Flaherty, MD, MS Professor of Medicine Director, University of Michigan Interstitial Lung Disease Program Chair, Pulmonary Fibrosis Foundation Clinical Care Network/Registry Steering Committee Ann Arbor, MI
Dr. Flaherty has disclosed the following: Grant/Research Support: Boehringer Ingelheim, Roche/Genentech Consultant: Aeolus, Afferent, Boehringer Ingelheim, Fibrogen, Roche/Genentech, Sanofi-Genzyme, Veracyte
David J. Lederer, MD, MS Associate Professor of Medicine Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY
Dr. Lederer has disclosed the following: Consultant: FibroGen, Global Blood Therapeutics, Inc., Philips Respironics, Roche/Genentech, Sanofi Genzyme, Veracyte
Accredited Provider Disclosures
Penn State staff involved in the development and review of this activity have nothing to disclose.
Publishing Staff disclosures
The MCM Education planners and managers have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6190-18-T.